Sign In
Buy STOK
$29.46
+0.780 (+2.72%)
At Close: Jun 03, 2026
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts
01:32am, Monday, 22'nd Dec 2025
Stoke Therapeutics, Inc. (NASDAQ: STOK - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the company, MarketBeat reports. Two investment analy
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK
03:27am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. raised its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 67.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Excha
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Tuesday, 16'th Dec 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%
01:15pm, Tuesday, 16'th Dec 2025
Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
08:59pm, Wednesday, 10'th Dec 2025
Barry Ticho, Chief Medical Officer at Stoke Therapeutics (STOK +12.08%), executed an option exercise and open-market sale of 5,358 common shares for a total consideration of approximately $167,115 on
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in sei
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
07:30am, Monday, 01'st Dec 2025
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Analysts
02:12am, Thursday, 27'th Nov 2025
Stoke Therapeutics, Inc. (NASDAQ: STOK - Get Free Report) has been given an average rating of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Two investmen
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Tuesday, 18'th Nov 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
Aviva PLC Takes $499,000 Position in Stoke Therapeutics, Inc. $STOK
04:01am, Friday, 14'th Nov 2025
Aviva PLC bought a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The
All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy
01:01pm, Wednesday, 05'th Nov 2025
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
07:01pm, Tuesday, 04'th Nov 2025
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.47 per share a year ago.
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
04:01pm, Tuesday, 04'th Nov 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
